Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
03 nov. 2022 12h30 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
02 nov. 2022 12h30 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
27 oct. 2022 16h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Announces Planned Departure of Chief Financial Officer
27 oct. 2022 16h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Reports Corporate Highlights and H1 2022 Financials
25 août 2022 16h30 HE
|
Molecular Partners
Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of...
Molecular Partners Half Year 2022 News Release and Investor Call Details
18 août 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2
21 juil. 2022 11h30 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Participation in Scientific Conferences
10 juin 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum
12 mai 2022 16h05 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners to Participate in Upcoming Healthcare Investor Conferences
11 mai 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...